Morgan Stanley
XTLB

Morgan Stanley’s XTL Biopharmaceuticals XTLB Stock Holding History

Morgan Stanley’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$24 – 8607
2026
Q1 		$24 Sell
10
-425
-98% -$1.35K ﹤0.01% 8144
2025
Q4 		$1.01K Sell
435
-2,068
-83% -$8.37K ﹤0.01% 7364
2025
Q3 		$11.7K Sell
2,503
-250
-9% -$1.39K ﹤0.01% 6860
2025
Q2 		$12.6K Sell
2,753
-560
-17% -$2.72K ﹤0.01% 6790
2025
Q1 		$15.8K Sell
3,313
-1,275
-28% -$7.81K ﹤0.01% 6646
2024
Q4 		$37.2K Sell
4,588
-2,025
-31% -$15.4K ﹤0.01% 6381
2024
Q3 		$63.6K Sell
6,613
-1,675
-20% -$17.5K ﹤0.01% 6150
2024
Q2 		$80.6K Sell
8,288
-1,505
-15% -$15.4K ﹤0.01% 6037
2024
Q1 		$110K Sell
9,793
-10,093
-51% -$46.7K ﹤0.01% 5952
2023
Q4 		$80.3K Buy
19,886
+9,743
+96% +$37K ﹤0.01% 6231
2023
Q3 		$36.4K Sell
10,143
-150
-1% -$555 ﹤0.01% 6292
2023
Q2 		$41.2K Sell
10,293
-150
-1% -$734 ﹤0.01% 6290
2023
Q1 		$54.7K Sell
10,443
-300
-3% -$1.56K ﹤0.01% 6255
2022
Q4 		$52K Sell
10,743
-575
-5% -$2.85K ﹤0.01% 6276
2022
Q3 		$50K Sell
11,318
-875
-7% -$5.43K ﹤0.01% 6410
2022
Q2 		$74K Sell
12,193
-125
-1% -$970 ﹤0.01% 6424
2022
Q1 		$102K Sell
12,318
-450
-4% -$4.42K ﹤0.01% 6297
2021
Q4 		$141K Sell
12,768
-150
-1% -$2.08K ﹤0.01% 6251
2021
Q3 		$226K Sell
12,918
-598
-4% -$9.63K ﹤0.01% 5935
2021
Q2 		$216K Buy
13,516
+9
+0.1% +$124 ﹤0.01% 5975
2021
Q1 		$180K Sell
13,507
-699
-5% -$9.63K ﹤0.01% 5715
2020
Q4 		$172K Buy
14,206
+2,348
+20% +$22.3K ﹤0.01% 5666
2020
Q3 		$90K Buy
11,858
+1,400
+13% +$9.71K ﹤0.01% 5476
2020
Q2 		$67K Buy
10,458
+475
+5% +$2.46K ﹤0.01% 5570
2020
Q1 		$47K Buy
9,983
+775
+8% +$3.99K ﹤0.01% 5485
2019
Q4 		$50K Buy
9,208
+175
+2% +$942 ﹤0.01% 5858
2019
Q3 		$49K Buy
9,033
+25
+0.3% +$186 ﹤0.01% 5732
2019
Q2 		$72K Buy
9,008
+325
+4% +$2.86K ﹤0.01% 5463
2019
Q1 		$82K Buy
8,683
+400
+5% +$3.62K ﹤0.01% 5484
2018
Q4 		$57K Buy
8,283
+2,400
+41% +$22.5K ﹤0.01% 5720
2018
Q3 		$52K Buy
5,883
+843
+17% +$6.17K ﹤0.01% 5869
2018
Q2 		$37K Buy
5,040
+1,075
+27% +$8.07K ﹤0.01% 5993
2018
Q1 		$27K Buy
3,965
+1,275
+47% +$10.4K ﹤0.01% 6066
2017
Q4 		$25K Buy
2,690
+400
+17% +$3.84K ﹤0.01% 6022
2017
Q3 		$22K Buy
2,290
+625
+38% +$7.35K ﹤0.01% 6001
2017
Q2 		$21K Buy
1,665
+275
+20% +$2.91K ﹤0.01% 6074
2017
Q1 		$15K Buy
1,390
+1,220
+718% +$13.7K ﹤0.01% 6154
2016
Q4 		$2K Buy
170
+40
+31% +$607 ﹤0.01% 6389
2016
Q3 		$2K Buy
130
+100
+333% +$2.17K ﹤0.01% 6373
2016
Q2 		$1K Buy
+30
New +$644 ﹤0.01% 6449
2016
Q1 		– Hold
0
– – – 6731
2015
Q4 		– Hold
0
– – – 6813
2015
Q3 		– Hold
0
– – – 6736
2015
Q2 		– Hold
0
– – – 6760
2015
Q1 		– Hold
0
– – – 6666
2014
Q4 		– Hold
0
– – – 6680
2014
Q3 		– Hold
0
– – – 6668
2014
Q2 		– Hold
0
– – – 6607
2014
Q1 		– Hold
0
– – – 6551

Other funds holding XTLB

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's XTLB Position: Q2 2026 in Review

Morgan Stanley sold out of XTL Biopharmaceuticals (XTLB) in Q2 2026, closing a stake of 10 shares — an estimated $24 sold.

Morgan Stanley first reported a position in XTLB in Q2 2016 and held it in 40 quarters. The position peaked at $226K in Q3 2021. 3 funds tracked by Wall St. Rank hold XTLB as of Q2 2026.

  • Morgan Stanley reported no remaining XTL Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Morgan Stanley sold 10 XTL Biopharmaceuticals shares in Q2 2026, an estimated $24.
  • Morgan Stanley first reported a position in XTL Biopharmaceuticals in Q2 2016 and held it in 40 quarters.
  • Morgan Stanley's XTL Biopharmaceuticals position peaked at $226K in Q3 2021.
  • 3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.